Amaç & Hipotez:Toxic anterior segment syndrome (TASS) is an acute, non-infectious postoperative inflammatory reaction of the anterior segment of the eye, that usually develops 12-48 hours after intraocular surgery.
📊
Temel Bulgular & Veri:Mostly, the inflammation is resolved with appropriate treatment within days or weeks, with a good outcome; however, infrequently complications such as permanent corneal edema, secondary glaucoma, and chronic macular edema can occur jeopardizing the visual outcome.
💡
Sonuç & Katkı:Keywords: Macular edema, Toxic anterior segment syndrome.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Özet
Toxic anterior segment syndrome (TASS) is an acute, non-infectious postoperative inflammatory reaction of the anterior segment of the eye, that usually develops 12-48 hours after intraocular surgery. Mostly, the inflammation is resolved with appropriate treatment within days or weeks, with a good outcome; however, infrequently complications such as permanent corneal edema, secondary glaucoma, and chronic macular edema can occur jeopardizing the visual outcome. The aim of this study is to present the clinical outcomes of intravitreal aflibercept injection in a case with macular edema associated with TASS. Keywords: Macular edema, Toxic anterior segment syndrome.
🔖
Bu Makaleye Atıf Yap
CANAN, H. (2021). Effectiveness of Aflibercept in a Case of TASS-Associated Macular Edema. Retina-Vitreus, Cilt: 30 - Sayı: 3, 308–311. https://ajindex.com/articles/400348
Kaynakça (13)
Monson MC, Mamalis N, Olson RJ. Toxic anterior segment inflammation following cataract surgery. J Cataract Refract Surg. 1992;18:184-9
Shouchane-Blum K, Dotan A, Bahar I. The evolution of toxic anterior segment syndrome. Curr Opin Ophthalmol. 2019;30:50- 5
Park CY, Lee JK, Chuck RS. Toxic anterior segment syndromean updated review. BMC Ophthalmol. 2018;18:276
Sızmaz S, Küçükerdönmez C, Çetinkaya A, et al. A New Potential Cause in the Development of Toxic Anterior Segment Syndrome: Fibrin Glue.Turk J Ophthalmol 2014; 44: 280-3. doi: 10.4274/tjo.69885
Zur D, Fischer N, Tufail A, et al. Postsurgical cystoid macular edema. Eur J Ophthalmol. 2011;21 Suppl6:S62-8. doi: 10.5301/ EJO.2010.6058 6. Arevalo JF, Maia M, Garcia-Amaris RA, et al; Pan-American Collaborative Retina Study Group. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology. 2009;116:1481-7
Lin CJ, Tsai YY. Use of aflibercept for the management of refractory pseudophakic macular edema in Irvine-Gass syndrome and literature review. Retin Cases Brief Rep. 2018;12:59-62
Guo S, Patel S, Baumrind B, et al. Management of pseudophakic cystoid macular edema. Surv Ophthalmol. 2015;60:123-37
Bellocq D, Korobelnik JF, Burillon C, et al. Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODIC study. Br J Ophthalmol. 2015 Jul;99:979-83
Sengupta S, Chang DF, Gandhi R, et al. Incidence and long-term outcomes of toxic anterior segment syndrome at Aravind Eye Hospital. J Cataract Refract Surg. 2011;37:1673-8
Ugurbas SC, Akova YA. Toxic anterior segment syndrome presenting as isolated cystoid macular edema after removal of entrapped ophthalmic ointment. Cutan Ocul Toxicol. 2010;29:221-3
Pham B, Thomas SM, Lillie E, et al. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. BMJ Open. 2019;9:e022031
Ian Y Wong, Lawrence P Iu, Hideki Koizumi et al. The inner segment/outer segment junction: what have we learnt so far?. Curr Opin Ophthalmol. 2012;23:210-8
Allan A Hunter, Sara P Modjtahedi, Kuumba Long,et al. Improving visual outcomes by preserving outer retina morphology in eyes with resolved pseudophakic cystoid macular edema.J Cataract Refract Surg. 2014;40:626-31.